Daily Sepsis Research Analysis
Top sepsis research today highlights: (1) a multicenter pediatric study integrating endothelial biomarkers with clinical data to predict persistent sepsis-associated acute respiratory dysfunction by day 3; (2) a nationwide prospective cohort showing that elevated troponin at sepsis recognition does not independently predict worse hospital outcomes; and (3) a randomized trial finding no superiority of continuous over intermittent beta-lactam infusion for clinical cure in ICU patients with sepsis.
Summary
Top sepsis research today highlights: (1) a multicenter pediatric study integrating endothelial biomarkers with clinical data to predict persistent sepsis-associated acute respiratory dysfunction by day 3; (2) a nationwide prospective cohort showing that elevated troponin at sepsis recognition does not independently predict worse hospital outcomes; and (3) a randomized trial finding no superiority of continuous over intermittent beta-lactam infusion for clinical cure in ICU patients with sepsis.
Research Themes
- Biomarker-driven prognostication in pediatric sepsis
- Therapy optimization and antimicrobial dosing strategies
- Risk stratification and triage in adult sepsis
Selected Articles
1. Derivation and Validation of a Clinical and Endothelial Biomarker Risk Model to Predict Persistent Pediatric Sepsis-Associated Acute Respiratory Dysfunction.
Using prospectively collected multicenter data, the authors derived and validated machine-learning models that integrate day 1 clinical variables and endothelial biomarkers to predict persistent sepsis-associated acute respiratory dysfunction by day 3 in children. High-risk patients had higher mortality, longer ventilation, and longer PICU stays.
Impact: Provides an actionable, early prognostic tool grounded in endothelial pathobiology to enable enrichment and targeted interventions in pediatric sepsis trials.
Clinical Implications: Day-1 endothelial biomarkers combined with clinical variables can help identify children at high risk for persistent respiratory dysfunction, informing early escalation, resource allocation, and trial enrollment.
Key Findings
- Machine-learning models (TreeNet and CART) using day-1 clinical variables and endothelial biomarkers predicted day-3 sepsis-associated acute respiratory dysfunction.
- High-risk classification was associated with increased mortality, prolonged mechanical ventilation, and longer PICU length of stay.
- Model performance was comparable across TreeNet and CART and was validated in an independent test cohort.
Methodological Strengths
- Prospectively enrolled multicenter derivation with independent test cohort
- Integration of endothelial biomarkers reflecting ARD pathophysiology with machine-learning methods
Limitations
- External validation limited to a single-center test cohort; broader generalizability not yet established
- Day-1 measurements only; temporal dynamics and interventional impact not assessed
Future Directions: Prospective multicenter external validation, assessment of real-time implementation thresholds, and interventional studies to determine whether biomarker-guided strategies improve outcomes.
BACKGROUND: Sepsis-associated ARDS results in high morbidity and mortality in children. However, heterogeneity among patients makes identifying those at risk of persistent acute respiratory dysfunction challenging. Endothelial dysfunction is a key feature of ARDS pathophysiologic characteristics, contributing to lung injury in sepsis. Incorporating endothelial biomarkers into risk models may enhance prediction of those with persistent acute respiratory dysfunction. RESEARCH QUESTION: Can clinical variables and endothelial biomarkers measured early in the course of sepsis predict risk of persistent acute respiratory dysfunction among critically ill children? STUDY DESIGN AND METHODS: This was a multicenter derivation and single center test cohort study of prospectively enrolled children with sepsis. The derivation cohort was split into training and holdout validation sets. We trained TreeNet (Minitab, LLC) and classification and regression tree (CART) models using clinical and endothelial biomarkers measured on day 1 of septic shock to predict risk of sepsis-associated acute respiratory dysfunction (SA ARD) on day 3. The performance of the CART model was tested in the holdout validation data set and in the independent test cohort. RESULTS: In the derivation (n = 625) and test (n = 162) cohorts, children with day 3 SA ARD showed increased mortality, length of mechanical ventilation, and PICU length of stay compared with those without. The TreeNet and CART models yielded comparable results. The variables included in the final CART model were presence of SA ARD on day 1, Pao INTERPRETATION: We derived and validated predictive models incorporating clinical and endothelial biomarkers to identify pediatric patients with septic shock at high risk of persistent acute respiratory dysfunction. Pending prospective validation, such models may facilitate enrichment and targeted intervention in future clinical trials.
2. Impact of Elevated Troponin Level at the Time of Sepsis Recognition on the Clinical Outcomes: A Propensity Score-Matched Cohort Study.
In a nationwide, multicenter prospective cohort without prior cardiovascular disease, elevated troponin at the time of sepsis recognition was not associated with higher hospital mortality after propensity score matching. The findings challenge reliance on single-timepoint troponin elevation for sepsis risk stratification.
Impact: Clarifies a common clinical uncertainty by showing that isolated troponin elevation at sepsis recognition is not an independent prognostic marker, potentially reducing unnecessary downstream testing and refocusing resources.
Clinical Implications: Avoid overinterpreting isolated troponin elevation at sepsis recognition; integrate serial measurements and broader clinical context for cardiac assessment rather than reflexive invasive workups.
Key Findings
- In 2141 adults with sepsis (no prior CVD), elevated troponin at recognition was not associated with higher hospital mortality after propensity score matching (523 pairs).
- No significant differences in other clinical outcomes were observed between elevated and normal troponin groups.
- Findings suggest limited prognostic value of single-timepoint troponin elevation at sepsis recognition.
Methodological Strengths
- Nationwide multicenter prospective registry with large sample size
- Propensity score matching to address confounding at baseline
Limitations
- Troponin assays and reference ranges varied across institutions
- Single timepoint measurement at sepsis recognition; serial dynamics not assessed
Future Directions: Evaluate serial high-sensitivity troponin with echocardiography and other biomarkers to phenotype septic cardiomyopathy and guide targeted therapies.
BACKGROUND: Sepsis-induced cardiac dysfunction, known as septic cardiomyopathy, is a common complication associated with increased mortality. Cardiac troponins serve as markers for myocardial injury and are frequently elevated in patients with sepsis. However, the role of troponin elevation at sepsis recognition in risk stratification remains controversial. METHODS AND RESULTS: This nationwide multicenter prospective cohort study analyzed 2141 adult patients with sepsis without prior cardiovascular disease from the Korean Sepsis Alliance registry. These patients were classified as having either elevated troponin levels or troponin levels in the normal range at the time of sepsis recognition, according to the reference ranges specific to each participating institution. The primary outcome was hospital mortality, and propensity score matching was used to control for confounding factors. In the propensity score-matched cohort (523 pairs), there were no significant differences in hospital mortality (35.2% versus 32.7%, odds ratio [OR], 1.12 [95% CI, 0.86-1.44], CONCLUSIONS: Troponin elevation at sepsis recognition was not significantly associated with increased hospital mortality or worse clinical outcomes in patients with sepsis.
3. Continuous versus intermittent bolus dosing of beta-lactam antibiotics in a South African multi-disciplinary intensive care unit: A randomized controlled trial.
In a randomized trial of 122 ICU patients with sepsis, continuous beta-lactam infusion did not improve day-14 clinical cure compared with intermittent bolus dosing. ICU length of stay and mortality were similar, with a non-significant trend toward lower day-90 mortality in the continuous infusion group.
Impact: Directly informs a common dosing controversy in sepsis management, suggesting that continuous infusion may not confer routine clinical benefit over intermittent dosing.
Clinical Implications: Either dosing strategy may be reasonable in ICU sepsis; continuous infusion should be targeted to specific PK/PD scenarios (e.g., high MIC pathogens, altered clearance) and ideally guided by therapeutic drug monitoring.
Key Findings
- No significant difference in day-14 clinical cure between continuous infusion and intermittent bolus dosing.
- ICU length of stay and antibiotic duration were similar across groups.
- A trend toward lower day-90 mortality with continuous infusion did not reach statistical significance.
Methodological Strengths
- Randomized design with balanced baseline characteristics
- Pragmatic inclusion of multiple beta-lactam agents in a real-world ICU setting
Limitations
- Single-center study with modest sample size; limited power for mortality endpoints
- No therapeutic drug monitoring or PK/PD target attainment assessment
Future Directions: Large multicenter trials integrating therapeutic drug monitoring should test whether specific subgroups (e.g., high MIC, augmented renal clearance, CRRT) benefit from continuous infusion.
BACKGROUND: Beta-lactams exhibit time-dependent bactericidal effects with continuous infusion (CI) suggested to provide superior antibiotic concentrations compared to intermittent bolus (IB). OBJECTIVE: To determine whether beta-lactam CI improves day 14 clinical cure compared to IB in a South African, multi-disciplinary intensive care unit (ICU). METHODS: Adult patients with sepsis receiving amoxicillin-clavulanate, piperacillin-tazobactam, imipenem-cilastatin and meropenem were randomized to 24-hour CI or IB. On screening, patients who received study antibiotics for more than 24 h, pregnant patients or patients on renal replacement therapy were excluded. The primary outcome, clinical cure, was defined as completion of antibiotics by day 14 without recommencement within 48 h. Secondary outcomes included ICU length of stay (LOS), ICU, day 28 and day 90 mortality. RESULTS: We enrolled 122 patients. The groups were balanced for baseline age, weight, sex, severity of illness, organ support, HIV status, diagnostic category and site of infection. Median antibiotic duration, CI group, 7 days (IQR 5-8.5) vs. IB group, 6 days (IQR 4-8), p=0.191, and median ICU LOS, CI, 9.5 days (IQR 6-15.5) vs. IB, 9 days (IQR 5-16), p= 0.575, were similar. Clinical cure in the CI group was 81% (52/64) vs. 74.1% (43/58) in the IB group), p=0.345. Day 90 relative risk of death was 0,57, 95% Confidence Interval 0.32 - 1.01) for the CI group compared to IB. CONCLUSION: Among critically ill patients meeting the sepsis-3 definition, this study could not demonstrate the superiority of continuous infusion of beta-lactam antibiotics compared to intermittent bolus in achieving a clinical cure.